CRISPR Knockout AAV Library
abm‘s CRISPR Knockout sgRNA AAV Viruses have a broad host range and low immunogenicity, perfect forin vivoCRISPR experiments. AAV is non-integrating, so there is less risk of interfering with host gene expression. We offer a collection of Knockout AAVs that express sgRNAs targeting any human, mouse, or rat gene, compatible with either spCas9 or saCas9. In addition to sgRNA-only vectors, we also offer an All-In-One AAV option, which expresses sgRNA and saCas9 nuclease from the same vector.
Key Features
- Collection of sgRNAs for knockout of your gene of interest with either saCas9 or spCas9. Human, mouse, and rat gene targets are available.
- AAV delivery for low immunogenicity and non-integrating expression of sgRNA and/or saCas9.
- Available expressing sgRNA alone, or as an All-In-One construct which expresses both sgRNA and saCas9.
- Comes as a set or pool of three sgRNA AAVs for assurance of efficient gene knockout.
- Available as AAV serotypes 1 to 11 for high transduction efficiency in specific tissues.
For multiplex gRNA expression from lentiviral vector, use our Custom Multiplex gRNA Service.
For knockout of up to 100 target genes, take advantage of our pooled Custom Targeted Lentiviral sgRNA Library Service.
Popular Products
- AAV Virus Titration Kit
- CRISPR Control Vectors and Viruses
- Custom CRISPR sgRNA AAV Vectors & Viruses
Additional Resources on CRISPR Technology
Search Library
Primary Cells Collection
We offer a wide variety of primary cell lines
across more than 20 different cell systems.
Can’t find the cell line you’re looking for? Contact info@itsbio.co.kr.
abm web site 제품 검색 입니다.
Top Publications
01 |
Regulation of NKT cell-mediated immune responses to tumours and liver inflammation by mitochondrial PGAM5-Drp1 signalling. |
02 |
Isorhapontigenin (ISO) inhibits invasive bladder cancer (BC) formation in vivo and human BC invasion in vitro by targeting STAT1/FOXO1 Axis. Jiang, G. et al. Cancer Prev Res. Published Online First April 14, 2016. doi: 10.1158/1940-6207.CAPR-15-0338 |
03 | Clinical significance of SNORA42 as an oncogene and a prognostic biomarker in colorectal cancer. Okugawa, Y et al. Gut (2015) doi:10.1136/gutjnl-2015-309359 |
Browse Products
Unit: 1.0 μg per target, 5 x 200 μl, 300 μl per target, 1.0 ml, 1 x 106 cells/1.0 ml
Unit: 1.0 μg per target, 5 x 200 μl, 300 μl per target, 1.0 ml, 1 x 106 cells/1.0 ml
Unit: 1.0 μg per target, 5 x 200 μl, 300 μl per target, 1.0 ml, 1 x 106 cells/1.0 ml
Unit: 1.0 μg per target, 5 x 200 μl, 300 μl per target, 1.0 ml, 1 x 106 cells/1.0 ml
Unit: 1.0 μg per target, 5 x 200 μl, 300 μl per target, 1.0 ml, 1 x 106 cells/1.0 ml
Unit: 1.0 μg per target, 5 x 200 μl, 300 μl per target, 1.0 ml, 1 x 106 cells/1.0 ml
Unit: 1.0 μg per target, 5 x 200 μl, 300 μl per target, 1.0 ml, 1 x 106 cells/1.0 ml
Unit: 1.0 μg per target, 5 x 200 μl, 300 μl per target, 1.0 ml, 1 x 106 cells/1.0 ml
Unit: 1.0 μg per target, 5 x 200 μl, 300 μl per target, 1.0 ml, 1 x 106 cells/1.0 ml